Xintela AB (publ) (STO:XINT)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.260
+0.013 (5.26%)
At close: Mar 6, 2026
-34.67%
Market Cap 223.93M
Revenue (ttm) 2.28M
Net Income (ttm) -48.56M
Shares Out 861.27M
EPS (ttm) -0.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 225,668
Average Volume 303,588
Open 0.267
Previous Close 0.247
Day's Range 0.241 - 0.267
52-Week Range 0.238 - 0.700
Beta 2.33
RSI 44.02
Earnings Date Feb 27, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 13
Stock Exchange Nasdaq Stockholm
Ticker Symbol XINT
Full Company Profile

Financial Performance

In 2025, Xintela AB's revenue was 2.28 million, a decrease of -45.86% compared to the previous year's 4.22 million. Losses were -48.56 million, 23.9% more than in 2024.

Financial Statements

News

There is no news available yet.